Oncology Pharma Inc

Company Profile

Oncology Pharma Inc had its IPO on under the ticker symbol ONPH.

The company operates in the Healthcare sector and Biotechnology industry. Oncology Pharma Inc has a staff strength of 0 employees.

Stock update

Shares of Oncology Pharma Inc opened at $0.18 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.17 - $0.18, and closed at $0.17.

This is a +0.06% increase from the previous day's closing price.

A total volume of 62,810 shares were traded at the close of the day’s session.

In the last one week, shares of Oncology Pharma Inc have increased by +0.17%.

Oncology Pharma Inc's Key Ratios

Oncology Pharma Inc has a market cap of $756681, indicating a price to book ratio of 0 and a price to sales ratio of 66.2845.

In the last 12-months Oncology Pharma Inc’s revenue was $10214 with a gross profit of $10214 and an EBITDA of $-8650. The EBITDA ratio measures Oncology Pharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Oncology Pharma Inc’s operating margin was -141.66% while its return on assets stood at 0% with a return of equity of 0%.

In Q4, Oncology Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Oncology Pharma Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Oncology Pharma Inc’s profitability.

Oncology Pharma Inc stock is trading at a EV to sales ratio of 8.0498 and a EV to EBITDA ratio of -1.2935. Its price to sales ratio in the trailing 12-months stood at 66.2845.

Oncology Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$403025.00

Total Liabilities

$809329.00

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Oncology Pharma Inc ended 2024 with $403025.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $403025.00 while shareholder equity stood at $-407304.00.

Oncology Pharma Inc ended 2024 with $0 in deferred long-term liabilities, $809329.00 in other current liabilities, 411949.00 in common stock, $-26220929.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3208.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Oncology Pharma Inc’s total current assets stands at $18208.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $15000.00 compared to accounts payable of $20800.00 and inventory worth $0.

In 2024, Oncology Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Oncology Pharma Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.17

52-Week High

$1.36

52-Week Low

$0.156

Analyst Target Price

$

Oncology Pharma Inc stock is currently trading at $0.17 per share. It touched a 52-week high of $1.36 and a 52-week low of $1.36. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.31 and 200-day moving average was $0.74 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 3.7% are held by institutions.